There are currently more than 7 million patients taking a direct oral anticoagulant (DOAC),
with more new prescriptions per year than warfarin. Despite impressive efficacy and safety …

Background: Direct oral anticoagulants (DOACs) are known to have similar efficacy with a
decreased risk of bleeding when compared to warfarin for the treatment of venous …

Obesity is a known risk factor for venous thromboembolism (VTE) and poses a unique set of
challenges in anticoagulation management. We report a 10-year experience of VTE …

Introduction Guidelines have endorsed non-vitamin K antagonist oral anticoagulants
(NOACs), consisting of factor Xa inhibitors (xabans) and direct thrombin inhibitors, as the first …

Bodega et al.'s recent report on the efficacy and safety of direct oral anticoagulants (DOACs)
in patients with nonvalvular atrial fibrillation and extreme body weight reinforces recent …

Direct oral anticoagulants (DOACs) are widely used as first-line treatment for pulmonary
embolism (PE) in patients without contraindications [1]; however, limited data exists on the …

Direct oral anticoagulants (DOACs) have become the standard of care for acute and long-
term therapy for venous thromboembolism (VTE) due to their efficacy and safety profiles. The …

This study was conducted to evaluate the efficacy and safety of apixaban versus warfarin in
morbidly obese patients. A total of 250 morbidly obese patients with a body mass index …

Background: Direct oral anticoagulants (DOACs) are increasingly prescribed for the
treatment of venous thromboembolism (VTE). However, little is known regarding …

Obesity is a worldwide health problem at increasing incidence associated with high
morbidity and mortality. Although obesity increases patients' cardiovascular (CV) risk, more …